eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Risk of C1q variation in systemic lupus erythematosus: a meta-analysis with Trial Sequential Analysis

Hong Wang
1, 2
,
Tingrui Wang
1, 2
,
Haili Wang
1, 2
,
Yue Wu
1, 2
,
Lingling Wu
1, 2
,
Huayun Ling
1, 2
,
Dong-Qing Ye
1, 2
,
Bin Wang
1, 2

1.
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
2.
Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Hefei, Anhui, China
Adv Dermatol Allergol 2022; XXXIX (2): 353-361
Online publish date: 2022/05/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction and aim
Systemic lupus erythematosus (SLE) is an autoimmune disease closely related to the immune system. C1q is an important component of complement system. However, the correlation between C1q gene polymorphism and SLE has not been completely unified.
Aim: The primary aim of this meta-analysis was to examine the association between C1q polymorphisms and the risk of SLE.

Material and methods
All relevant articles were retrieved from PubMed, Web of Science and CNKI until June 2020. Pooled OR and 95% CI with random model were used to evaluate the strength of the association between C1q polymorphisms and SLE. Considering the limited number of studies, Trial Sequential Analysis (TSA) was applied to estimate whether the information was sufficient to make reliable and conclusive evidence. Both Egg’s test and trim and fill method were performed to assess the publication bias.

Results
Eight articles were included in this meta-analysis. The pooled results showed that C1q rs631090 was associated with SLE only in the homozygous and recessive model (allelic model: 1.169 (0.632–2.162), homozygous model: 2.342 (1.239–4.427), heterozygous model: 0.983 (0.395–2.448), dominant model: 1.036 (0.418–2.567), recessive model: 2.281 (1.227–4.239)) and there was no association between C1q rs172378 and rs292001 and SLE (rs172378 (allelic model: 1.071 (0.949–1.210), homozygous model: 1.172 (0.868–1.584), heterozygous model: 1.080 (0.892–1.306), dominant model: 1.100 (0.918–1.317), recessive model: 1.112 (0.863–1.431)); rs292001 (allelic model: 0.877 (0.657–1.170), homozygous model: 0.713 (0.320–1.589), heterozygous model: 0.714 (0.448–1.138), dominant model: 0.703 (0.414–1.196), recessive model: 0.927 (0.601–1.430)). Nevertheless, TSA showed that more information was needed to get more accurate results. There is no publication bias.

Conclusions
This meta-analysis suggested that C1q rs631090 but not rs172378 and rs292001 may be a potential susceptible factor associated with SLE. Nevertheless, due to the limited sample size in this meta-analysis, more large-scale association studies are still needed to confirm the results.

keywords:

systemic lupus erythematosus, C1q, Trial Sequential Analysis, polymorphism, meta-analysis

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.